Timothy Madden

6.2k citations

108 papers · 4.8k indexed · h-index 37

Impact in

Hematology top 0.5%
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
Oncology top 2%
- Cytokine Signaling Pathways and Interactions

Papers in

Hematology 25
- Acute Myeloid Leukemia Research 13
- Hematopoietic Stem Cell Transplantation 11
Oncology 43
- Cancer Treatment and Pharmacology 18

Co-authors: Robert A. Newman Hai T. Tran Richard E. Champlin Börje S. Andersson Waldemar Priebe Mary Johansen Peiying Yang Edward Felix
Journals: Journal of Clinical Oncology (20 papers)Cancer Research (10 papers)Biology of Blood and Marrow Transplantation (10 papers)Blood (7 papers)Molecular Cancer Therapeutics (5 papers)
Partner nations: United States Japan United Kingdom

In The Last Decade

Timothy Madden

107 papers receiving 4.7k citations

Peers

Countries citing papers authored by Timothy Madden

Since Specialization

Citations

This map shows the geographic impact of Timothy Madden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy Madden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy Madden more than expected).

Fields of papers citing papers by Timothy Madden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy Madden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy Madden. The network helps show where Timothy Madden may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Timothy Madden, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Timothy Madden Line = papers co-authored together Timothy Madden links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia Blood Advances ·Mark J. Levis, Alexander E. Perl, Gary J. Schiller, Amir T. Fathi, Gail J. Roboz, Eunice S. Wang, Jessica K. Altman, Trivikram Rajkhowa, Makoto Ando, Stanley Veerin Gunn, Ruth Ann Subach, Eva-Maria Putzier, Timothy Madden, Mary Johansen, K.Y. Cheung, Michael R. Kurman, Catherine C. Smith	2024	9
2	A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF‐10502‐01 for the treatment of advanced solid tumors Cancer ·Filip Jankú, Milind Javle, Shiraj Sen, Shubham Pant, Oleksandr Potuzhnij, Vivek Subbiah, 刘全昌, David Wages, Catherine Wheeler, Stanley Veerin Gunn, Kazunori Saeki, Ruth Ann Subach, Timothy Madden, Eva-Maria Putzier, Mary Johansen, K.Y. Cheung, Gerald S. Falchook	2023	1
3	Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma Clinical Cancer Research ·Michael A. Davies, Patricia S. Fox, Nicholas E. Papadopoulos, Agop Y. Bedikian, Wen-Jen Hwu, Alexander J. Lazar, Víctor G. Prieto, Kirk S. Culotta, Timothy Madden, Quanyun A. Xu, Sha Huang, Wanleng Deng, Chaan S. Ng, Sanjay Gupta, Wenbin Liu, Janet Dancey, James R. Wright, Roland L. Bassett, Patrick Hwu, Kevin B. Kim	2012	39
4	d-Glucose and d-mannose-based metabolic probes. Part 3: Synthesis of specifically deuterated d-glucose, d-mannose, and 2-deoxy-d-glucose Carbohydrate Research ·Izabela Fokt, Stanisław Skóra, Charles A. Conrad, Timothy Madden, Mark R. Emmett, Waldemar Priebe	2012	18
5	Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: A Children's Oncology Group study Pediatric Blood & Cancer ·John F. Kuttesch, Mark Krailo, Timothy Madden, Mary Johansen, Archie Bleyer	2009	40
6	d-Glucose- and d-mannose-based antimetabolites. Part 2. Facile synthesis of 2-deoxy-2-halo-d-glucoses and -d-mannoses Carbohydrate Research ·Izabela Fokt, Sławomir Szymański, Stanisław Skóra, Marcin Cybulski, Timothy Madden, Waldemar Priebe	2009	23
7	2-Deoxy-2-fluoro-D-mannose induces type II cell death in gliomas. Cancer Research ·赵晓飞, Izabela Fokt, Sławomir Szymański, A. S. Baryshnikov, Mary Johansen, Timothy Madden, Waldemar Priebe	2008	2
8	A Novel Small Molecule Inhibitor of Signal Transducers and Activators of Transcription 3 Reverses Immune Tolerance in Malignant Glioma Patients Cancer Research ·S. Farzana Hussain, Ling-Yuan Kong, 申吾三村, Charles A. Conrad, Timothy Madden, Paul Lartaud, Waldemar Priebe, Amy B. Heimberger	2007	246
9	Phase I clinical pharmacokinetics of RTA 744 (berubicin(B)), a blood-brain barrier penetrating anthracycline active against high grade glioma, and evaluation of its 13-hydroxy metabolite, berubicinol (B-ol) Molecular Cancer Therapeutics ·Chunrong Li, Charles A. Conrad, Mary Johansen, A. O. P., R Berend, Colin J. Meyer, Waldemar Priebe, Timothy Madden	2007	2
10	WP1066, a potent inhibitor of Jak2/STAT3 pathway inhibits pancreatic tumor growth both in vitro and in vivo Cancer Research ·Sushovan Guha, Arup Chakraborty, Sławomir Szymański, Izabela Fokt, James L. Abbruzzese, Chunrong Li, Timothy Madden, Waldemar Priebe	2007	7
11	Pharmacokinetics of Once-Daily IV Busulfan as Part of Pretransplantation Preparative Regimens: A Comparison with an Every 6-Hour Dosing Schedule Biology of Blood and Marrow Transplantation ·Timothy Madden, Marcos de Lima, R Berend, John Nguyen, L. S. Lavatell, Daniel Couriel, Sylwia Sroka, Elizabeth J. Shpall, Roy B. Jones, Richard E. Champlin, Börje S. Andersson	2007	97
12	The preclinical pharmacology of WP1066, a potent small molecule inhibitor of the JAK2/STAT3 pathway Cancer Research ·Timothy Madden, Chunrong Li, August Wilhelm Geissler, Kirk S. Culotta, Nicholas J. Donato, Mary Johansen, Yasuko Kondo, David H. Mack, Waldemar Priebe	2006	10
13	A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo Oncogene ·Arifumi Iwamaru, Sławomir Szymański, Eiji Iwado, Hiroshi Aoki, Tomohisa Yokoyama, Izabela Fokt, Kenneth R. Hess, C. Conrad, Timothy Madden, Raymond Sawaya, Seiji Kondo, Waldemar Priebe, Yasuko Kondo	2006	315
14	An LC/MS/MS based method to analyze tissue eicosanoids: Application to EPA-mediated alteration of prostaglandin metabolism Cancer Research ·Peiying Yang, Russell D. Klein, Edward Felix, Diana Chan, Timothy Madden, Robert A. Newman	2004	1
15	Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors Cancer Chemotherapy and Pharmacology ·Hai T. Tran, George R. Blumenschein, Charles Lu, Christina A. Meyers, Vali Papadimitrakopoulou, Frank V. Fossella, Ralph Zinner, Timothy Madden, Kangzi Khor, Vinay K. Puduvalli, Reginald F. Munden, Mylene T. Truong, Roy S. Herbst	2004	31
16	Inhibition of proliferation of PC3 cells by the branched‐chain fatty acid, 12‐methyltetradecanoic acid, is associated with inhibition of 5‐lipoxygenase The Prostate ·Peiying Yang, Peter D. Collin, Timothy Madden, Diana Chan, Fatemeh Abtahi, David J. McConkey, Robert A. Newman	2003	56
17	Intraocular carboplatin concentrations following intravenous administration for human intraocular retinoblastoma Ophthalmic Genetics ·David H. Abramson, Christopher M. Frank, Guillermo Chantada, O. G. Zeynetdinova, Johannes Rabiger‐Völlmer, Gema Ramírez, Ruth Gabriela Herrera Gómez, Adriana Fandiño, Hai T. Tran, Timothy Madden, Ira J. Dunkel	1999	26
18	Quantitation of dolastatin-10 using HPLC/electrospray ionization mass spectrometry: application in a phase I clinical trial Cancer Chemotherapy and Pharmacology ·D. A. Garteiz, Timothy Madden, M. Saha, Bernhard Babic, Yongshou, James L. Abbruzzese, F. Poingt, Robert A. Newman	1998	21
19	The Use of Microdialysis in Pharmacokinetics and Pharmacodynamics Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Mary Johansen, Said Karim Bounebache, Timothy Madden	1997	72
20	Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. Journal of Clinical Oncology ·Steven M. Kornblau, Elihu H. Estey, Timothy Madden, Hai T. Tran, Shihua Zhao, Ugo Consoli, Virginia Snell, Gisela Sanchez‐Williams, Hagop M. Kantarjian, Michael J. Keating, Robert A. Newman, Michael Andreeff	1997	75

About Timothy Madden

Timothy Madden is a scholar working on Hematology, Oncology, Cancer Research, Genetics and Pharmacology, having authored 108 papers that have together received 4.8k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (20 papers), Cancer Treatment and Pharmacology (18 papers), Acute Myeloid Leukemia Research (13 papers), Hematopoietic Stem Cell Transplantation (11 papers), Glioma Diagnosis and Treatment (10 papers), Cancer, Hypoxia, and Metabolism (9 papers), Acute Lymphoblastic Leukemia research (9 papers) and PI3K/AKT/mTOR signaling in cancer (8 papers). The work is most often cited by research in Hematology (1.2k citations), Oncology (1.6k citations), Cancer Research (714 citations), Genetics (369 citations) and Molecular Biology (2.1k citations). Timothy Madden has collaborated with scholars based in United States, Japan and United Kingdom. Frequent co-authors include Robert A. Newman, Hai T. Tran, Richard E. Champlin, Börje S. Andersson, Waldemar Priebe, Mary Johansen, Peiying Yang, Edward Felix, Kenneth R. Hess and Marcos de Lima. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Biology of Blood and Marrow Transplantation, Blood and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact